What is the role of erythropoiesis-stimulating agents (ESAs) in CKD, and what monitoring is essential?

• A. Treat CKD-associated anemia by stimulating red blood cell production; monitor hemoglobin and iron status to avoid overcorrection
• B. Increase white blood cell production to fight infection; monitor cholesterol
• C. Improve glomerular filtration rate; monitor creatinine clearance
• D. Lower blood pressure by increasing plasma volume

Answer: (A)

Erythropoiesis-stimulating agents in CKD are used to treat the anemia by signaling the bone marrow to produce more red blood cells, increasing hemoglobin and improving oxygen delivery to tissues. Their effectiveness relies on adequate iron availability, so iron stores are corrected and monitored during therapy to support erythropoiesis. Essential monitoring includes regular checks of hemoglobin (and hematocrit) to prevent overcorrection, with a typical target around 10–11 g/dL and cautious, gradual increases to avoid risks from rapid Hb rise. Alongside this, monitor iron status (ferritin and transferrin saturation) and blood pressure, since ESAs can raise blood pressure and, in some cases, contribute to thromboembolic events or, rarely, pure red cell aplasia. This combination of aiming to correct anemia while vigilantly tracking Hb, iron stores, and BP makes ESAs the appropriate choice for CKD-related anemia.